A peer-reviewed study published in Microorganisms evaluated outcomes across over 1,000 patients using Evvy’s diagnostic and treatment platform. Key findings include:
Symptom resolution: 75.5% of patients reported improvement within 4 weeks.
Reduced recurrence: At a mean follow-up of 4.4 months, recurrence was 30.0%—compared to >50% in standard care pathways.
Microbiome restoration: Significant shift from dysbiosis to Lactobacillus dominance, with notable reductions in BV-associated taxa (Gardnerella, Prevotella).
Remote efficacy: Clinical and microbiological success achieved entirely through at-home care.